Crossmark

Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodies: a pilot study

Crossref DOI link: https://doi.org/10.1186/s12882-025-03951-5

Published Online: 2025-01-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Guo, Zhiliang

Sa, Rula

Zhao, Daqiang

Li, Songxia

Guo, Hui

Zhu, Lan

Chen, Gang
Funding

Funding for this research was provided by:

Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2023-PT320-07)
License Information

Text and Data Mining valid from 2025-01-11

Version of Record valid from 2025-01-11
More Information

Article History

Received: 12 November 2024

Accepted: 6 January 2025

First Online: 11 January 2025

Declarations

:

: This study was approved by the Ethics Committee of Tongji Hospital, Wuhan, China (TJ-IRB20230729). All patients provided written informed consent before study inclusion.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below